4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study

MT Newswires Live

Oct 13, 2025

4D Molecular Therapeutics (FDMT) said Monday that the Cystic Fibrosis Foundation is providing up to $11 million in additional funding to support development of 4D-710 to treat cystic fibrosis lung disease.

The company said the first tranche of the funding, worth $7.5 million, closed in October. The second tranche will be available upon reaching certain clinical milestones.

The Foundation and 4D Molecular will also form a Joint Steering Committee with senior clinical development and regulatory expertise to further support strategic planning, guidance, and coordination of clinical and operational progress for the development of 4D-710, the company said.

The company said interim phase 1 data from its AEROW trial and a program update are expected by year-end

4D Molecular shares were down 1.9% in recent trading.

Price: 8.76, Change: -0.14, Percent Change: -1.57

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575400837"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575400837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575400837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575400837","market":"sh","top_or_hot":-1,"title":"4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> (FDMT) said Monday that the Cystic Fibrosis Foundation is providing up to $11 million in additional funding to support development of 4D-710 to treat cystic fibrosis lung disease.</p><p>The company said the first tranche of the funding, worth $7.5 million, closed in October. The second tranche will be available upon reaching certain clinical milestones.</p><p>The Foundation and 4D Molecular will also form a Joint Steering Committee with senior clinical development and regulatory expertise to further support strategic planning, guidance, and coordination of clinical and operational progress for the development of 4D-710, the company said.</p><p>The company said interim phase 1 data from its AEROW trial and a program update are expected by year-end</p><p>4D Molecular shares were down 1.9% in recent trading.</p><p>Price: 8.76, Change: -0.14, Percent Change: -1.57</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-13 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> (FDMT) said Monday that the Cystic Fibrosis Foundation is providing up to $11 million in additional funding to support development of 4D-710 to treat cystic fibrosis lung disease.</p><p>The company said the first tranche of the funding, worth $7.5 million, closed in October. The second tranche will be available upon reaching certain clinical milestones.</p><p>The Foundation and 4D Molecular will also form a Joint Steering Committee with senior clinical development and regulatory expertise to further support strategic planning, guidance, and coordination of clinical and operational progress for the development of 4D-710, the company said.</p><p>The company said interim phase 1 data from its AEROW trial and a program update are expected by year-end</p><p>4D Molecular shares were down 1.9% in recent trading.</p><p>Price: 8.76, Change: -0.14, Percent Change: -1.57</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FDMT","symbol_name":"4D Molecular Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575400837","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575400837","pubTimestamp":1760366096,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"4D Molecular Therapeutics  said Monday that the Cystic Fibrosis Foundation is providing up to $11 million in additional funding to support development of 4D-710 to treat cystic fibrosis lung disease.The company said the first tranche of the funding, worth $7.5 million, closed in October. The second tranche will be available upon reaching certain clinical milestones.The Foundation and 4D Molecular will also form a Joint Steering Committee with senior clinical development and regulatory expertise to further support strategic planning, guidance, and coordination of clinical and operational progress for the development of 4D-710, the company said.The company said interim phase 1 data from its AEROW trial and a program update are expected by year-end4D Molecular shares were down 1.9% in recent trading.Price: 8.76, Change: -0.14, Percent Change: -1.57","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FDMT":"4D Molecular Therapeutics","BK4139":"生物科技"},"translate_title":"4D Molecular Therapeutics获得1100万美元资金用于囊性纤维化研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDMT":1.5},"content_text":"4D Molecular Therapeutics (FDMT) said Monday that the Cystic Fibrosis Foundation is providing up to $11 million in additional funding to support development of 4D-710 to treat cystic fibrosis lung disease.The company said the first tranche of the funding, worth $7.5 million, closed in October. The second tranche will be available upon reaching certain clinical milestones.The Foundation and 4D Molecular will also form a Joint Steering Committee with senior clinical development and regulatory expertise to further support strategic planning, guidance, and coordination of clinical and operational progress for the development of 4D-710, the company said.The company said interim phase 1 data from its AEROW trial and a program update are expected by year-end4D Molecular shares were down 1.9% in recent trading.Price: 8.76, Change: -0.14, Percent Change: -1.57","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}